NCT04397770Unknown2 期
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma：a Single-center, Exploratory Clinical Study
Peking University Cancer Hospital & Institute0 个研究点目标入组 40 人开始时间: 2020年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 主要终点
- ORR
研究概览
简要总结
It is a single-center,exploratory clinical trial aimed to evaluate the objective response rate (ORR) of Camrelizumab combined with apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age:18-75 years, male or female.
- •Histopathologically confirmed recurrence, inoperable resection or metastatic acral melanoma (stage III/IV).
- •Has not received any systematic anti-tumor drug treatment.
- •Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.
- •Adequate organ function.
- •Life expectancy of greater than 12 weeks.
- •Patient has given written informed consent.
排除标准
- •Patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy.
- •Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR- 1210 formulation.
- •Subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ);
- •Subjects with any active autoimmune disease or history of autoimmune disease
- •Uncontrolled clinically significant heart disease, including but not limited to the following: (1) > NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;
- •Active infection or an unexplained fever > 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);
- •Received a live vaccine within 4 weeks of the first dose of study medication.
- •Pregnancy or breast feeding.
- •Decision of unsuitableness by principal investigator or physician-in charge.
研究组 & 干预措施
Camre+Apa+TMZ
Experimental
干预措施: SHR1210 (Drug)
Camre+Apa+TMZ
Experimental
干预措施: apatinib mesylate (Drug)
Camre+Apa+TMZ
Experimental
干预措施: Temozolomide Injection (Drug)
结局指标
主要结局
ORR
时间窗: Through study uncompletion, an average of 1 year
Objective Response Rate
次要结局
未报告次要终点
研究者
Jun Guo
Associate Director of Peking University Cancer Hospital
Peking University Cancer Hospital & Institute
相似试验
招募中
3 期
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral MelanomaAcral MelanomaNCT05789043Peking University Cancer Hospital & Institute140
进行中（未招募）
2 期
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerGastric and Gastroesophageal Junction (GEJ) AdenocarcinomaNCT06693128Ruijin Hospital80
Unknown
2 期
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic CarcinomaPancreatic CancerNCT04415385Zhejiang Cancer Hospital48
Unknown
不适用
Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian CancerImmune Checkpoint InhibitionNCT04507750Qianfoshan Hospital40
Unknown
不适用
Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell CarcinomaRenal Cell CarcinomaNCT04609293Peking University First Hospital30